Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High – Here’s What Happened

Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $20.01 and last traded at $19.81, with a volume of 12391502 shares trading hands. The stock had previously closed at $16.51.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of research analyst reports. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday. UBS Group boosted their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.88.

Teva Pharmaceutical Industries Trading Up 1.5 %

The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock’s 50 day moving average price is $17.61 and its 200-day moving average price is $17.45. The stock has a market capitalization of $24.02 billion, a PE ratio of -24.94, a PEG ratio of 0.99 and a beta of 0.79.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after purchasing an additional 664 shares during the period. Sequoia Financial Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares during the period. DGS Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after purchasing an additional 872 shares during the last quarter. Smithfield Trust Co raised its holdings in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Finally, Signaturefd LLC boosted its position in shares of Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after purchasing an additional 1,094 shares during the period. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.